Temozolomide: a novel oral alkylating agent.

  title={Temozolomide: a novel oral alkylating agent.},
  author={Sarah J. Danson and Mark R. Middleton},
  journal={Expert review of anticancer therapy},
  volume={1 1},
Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combination chemotherapy. Trials to date have focussed on its activity in advanced metastatic melanoma and high-grade malignant glioma. Investigations into other indications, in… CONTINUE READING